Phase II Trial GA101 Inbrutinib B CLL

NCT ID: NCT02666898

Last Updated: 2025-11-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 135 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-10-31
• Study Completion Date: 2023-09-30

Brief Summary

Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab nine months /

Study Part 1:

All patients will receive 8 courses of GA101 + ibrutinib 420mg PO every 28 days

Study Part 2:

After evaluation at D1 of month 9:

If patients are in CR with BM MRD < 10-4, they will continue ibrutinib alone at a dose of 420mg daily If patients have BM MRD >10-4 whatever IWCLL 2008 responses or PR they will receive four courses of GA101 + FC at 28-day intervals + Ibrutinib PO until final evaluation of M16

Detailed Description

Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab during nine months followed by a MRD-driven strategy. Assessment of response as well as bone marrow MRD evaluation will be performed at Day 1 month 9:

1. Patients reaching CR with marrow MRD below 10-4 threshold will continue ibrutinib during 6 additional months.

2. Patients in PR or bone marrow MRD > 10-4 will receive Ibrutinib during 6 additional months and 4 courses of FC+ GA101. At Day 1 Month 16, patients in CR but with MRD> 10-4 will continue Ibrutinib until progressive disease.

3. Patients in stable or progressive disease will be excluded out of the trial.

Final evaluation of response (with BM MRD) will be performed at Day 1 Month 16.

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Obinutuzumab and Ibrutinib CLL treatment

3 parts

PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:

GA101:

C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v

Ibrutinib:

D3 Month 1 to Day 30 Month 15: 420mg daily PO

PART 2: 4 cycles / 28 days

After evaluation at D1 month 9:

• patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily
• patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1
• Fludarabine : 40 mg/m² per os, days 2-4, / 28 days
• Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days
• Ibrutinib 420mg/day PO

PART 3 (only in GAI-FC+Ibru arm) :

After evaluation at D1 of M16:

• patients CR with BM MRD< 10-4, treatment stopped
• patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative.

Group Type: EXPERIMENTAL

GA101

Intervention Type: DRUG

Part 1 :6 cycles

Obinutuzumab/GA101:

First cycle:

D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v

Cycle 2 to 6 (every 28 days) :

D1 of every cycle: 1000 mg i.v PART 2 4 cycles

-patients have BM MRD >10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1

Ibrutinib

Intervention Type: DRUG

Part 1 :6 cycles

Cycle 2 to 6 (every 28 days) :Ibrutinib:

D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles

• patients in CR with BM MRD < 10-4 : Ibrutinib alone 420mg daily
• patients with BM MRD >10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine

Cyclophosphamide

Intervention Type: DRUG

PART 2 :

patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine

Fludarabine

Intervention Type: DRUG

PART 2 :

patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide

Interventions

GA101

Part 1 :6 cycles

Obinutuzumab/GA101:

First cycle:

D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v

Cycle 2 to 6 (every 28 days) :

D1 of every cycle: 1000 mg i.v PART 2 4 cycles

-patients have BM MRD >10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1

Intervention Type: DRUG

Ibrutinib

Part 1 :6 cycles

Cycle 2 to 6 (every 28 days) :Ibrutinib:

D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles

• patients in CR with BM MRD < 10-4 : Ibrutinib alone 420mg daily
• patients with BM MRD >10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine

Intervention Type: DRUG

Cyclophosphamide

PART 2 :

patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine

Intervention Type: DRUG

Fludarabine

PART 2 :

patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide

Intervention Type: DRUG

Other Intervention Names

Obinutuzumab; Imbruvica; Endoxan; Fludara

Eligibility Criteria

Inclusion Criteria

• Patient information and written informed consent
• Age 18 years or older
• Immunophenotypically confirmed B-CLL (IWCLL2008 and Matutes score 4 or 5)
• Binet stage C according to IWCLL 2008 criteria or Binet stage A and B with active disease could be considered for inclusion.
• Patients with no prior treatment (chemotherapy, radiotherapy, immunotherapy) except steroids for less than 1 month
• Absence of 17p deletion as assessed by FISH (< 10 % positive nuclei)
• Performance status ECOG < 2

Hematology values must be within the following limits:

• Absolute neutrophil count (ANC) <1 G/L independent of growth factor support
• Platelets <100 G/L or <50 G/L if bone marrow involvement independent of transfusion support in either situation

Biochemical values within the following limits:

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN)
• Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin
• Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockroft Gault≥ 40 mL/min/1.73m2
• Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug.
• Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [Beta-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study.
• Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study

Exclusion Criteria

• Binet stage A and B without active disease according to IWCLL 2008 criteria

• Known HIV seropositivity
• Hepatitis B or C seropositivity (unless clearly due to vaccination)
• Life expectancy < 6 months
• Patient refusal to perform the bone marrow biopsy for evaluation points
• Clinically significant auto-immune anemia
• Active second malignancy currently requiring treatment (except basal cell carcinoma in situ endometrial carcinoma and incidental prostate carcinoma) and/or less than 5 years CR after breast cancer
• Any severe co-morbid conditions such as Class III or IV heart failure, myocardial infarction within months, unstable angina, ventricular tachyarrhythmias requiring ongoing treatment, severe chronic obstructive pulmonary disease with hypoxemia, uncontrolled diabetes mellitus, or uncontrolled hypertension
• Concomitant disease requiring prolonged use of corticosteroids (> 1 month)
• Known hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the study drugs
• Contraindication to the use of Obinutuzumab.
• Contraindication to use of Ibrutinib
• Transformation to aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin lymphoma, or prolymphocytic leukaemia)
• Active bacterial, viral or fungal infection
• Abnormal renal function with creatinine clearance < 60 ml/min calculated according to the formula of Cockcroft and Gault
• Total bilirubin, gamma glutamyltransferase or transaminase levels > 2.5 ULN.
• Any coexisting medical or psychological condition that would preclude participation in the required study procedures
• Patient with mental deficiency preventing proper understanding of the requirements of treatment.
• Pregnant or breastfeeding women.
• Adult under law-control
• Fertile male and female patients who cannot or do not wish to use an effective method of contraception, during and for 18 months after the final treatment used for the purposes of the study.
• No affiliate to social security

• Major surgery within 4 weeks of randomization.
• Known central nervous system lymphoma.
• History of stroke or intracranial hemorrhage within 6 months prior to randomization.
• Requires anticoagulation with warfarin or equivalent vitamin K antagonists
• Requires treatment with strong CYP3A inhibitors.
• Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification.
• Vaccinated with live, attenuated vaccines within 4 weeks of randomization.
• Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics.
• Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

French Innovative Leukemia Organisation

OTHER

Sponsor Role: lead

Roche Pharma AG

INDUSTRY

Sponsor Role: collaborator

Janssen-Cilag Ltd.

INDUSTRY

Sponsor Role: collaborator

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Valérie ROUILLE, Mrs

Role: STUDY_DIRECTOR

French Innovative Leukemia Organisation

Pierre FEUGIER, MD PD

Role: PRINCIPAL_INVESTIGATOR

French Innovative Leukemia Organisation

Anne Sophie MICHALLET, MD

Role: PRINCIPAL_INVESTIGATOR

French Innovative Leukemia Organisation

Locations

Sponsor FILO

Tours, , France

Countries

France

References

Michallet AS, Letestu R, Le Garff-Tavernier M, Campos L, Ticchioni M, Dilhuydy MS, Morisset S, Rouille V, Mahe B, Laribi K, Villemagne B, Ferrant E, Tournilhac O, Delmer A, Molina L, Leblond V, Tomowiak C, de Guibert S, Orsini-Piocelle F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan-Graczyk M, Vilque JP, Schleinitz TA, Cymbalista F, Lepretre S, Levy V, Nguyen-Khac F, Feugier P. A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial. Blood Adv. 2023 Aug 8;7(15):3936-3945. doi: 10.1182/bloodadvances.2022009594.

Reference Type: DERIVED

PMID: 37026799 (View on PubMed)

Michallet AS, Letestu R, Le Garff-Tavernier M, Aanei C, Ticchioni M, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, De Guibert S, Orsini Piocelle F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan-Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Levy V, Nguyen-Khac F, Feugier P. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. Blood. 2021 Feb 25;137(8):1019-1023. doi: 10.1182/blood.2020008164.

Reference Type: DERIVED

PMID: 33167024 (View on PubMed)

Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, de Guibert S, Orsini F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Levy V, Nguyen-Khac F, Le Garff-Tavernier M, Aanei C, Ticchioni M, Letestu R, Feugier P. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16.

Reference Type: DERIVED

PMID: 31324600 (View on PubMed)

Related Links

http://www.filo-leucemie.org

FILO internet site

Other Identifiers

ICLL07GAI

Identifier Type: -

Identifier Source: org_study_id